Technical Analysis for PTN - Palatin Technologies, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -12.69% | |
| Fell Below 50 DMA | Bearish | -12.69% | |
| MACD Bearish Signal Line Cross | Bearish | -12.69% |
| Alert | Time |
|---|---|
| Down 10% | 1 day ago |
| Lower Bollinger Band Support | 1 day ago |
| Fell Below Lower Bollinger Band | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 5% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/14/2024
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Obesity Dysfunction Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Obesity Dysfunction Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.65 |
| 52 Week Low | 0.68 |
| Average Volume | 312,910 |
| 200-Day Moving Average | 1.78 |
| 50-Day Moving Average | 1.11 |
| 20-Day Moving Average | 1.15 |
| 10-Day Moving Average | 1.15 |
| Average True Range | 0.13 |
| RSI (14) | 37.89 |
| ADX | 21.85 |
| +DI | 21.35 |
| -DI | 23.98 |
| Chandelier Exit (Long, 3 ATRs) | 1.00 |
| Chandelier Exit (Short, 3 ATRs) | 1.32 |
| Upper Bollinger Bands | 1.32 |
| Lower Bollinger Band | 0.97 |
| Percent B (%b) | -0.1 |
| BandWidth | 30.54 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.02 |
| MACD Histogram | -0.017 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.16 | ||||
| Resistance 3 (R3) | 1.18 | 1.12 | 1.12 | ||
| Resistance 2 (R2) | 1.12 | 1.07 | 1.11 | 1.11 | |
| Resistance 1 (R1) | 1.03 | 1.03 | 1.00 | 1.01 | 1.10 |
| Pivot Point | 0.98 | 0.98 | 0.96 | 0.96 | 0.98 |
| Support 1 (S1) | 0.88 | 0.92 | 0.85 | 0.86 | 0.77 |
| Support 2 (S2) | 0.83 | 0.88 | 0.82 | 0.76 | |
| Support 3 (S3) | 0.73 | 0.83 | 0.75 | ||
| Support 4 (S4) | 0.71 |
